Changes in GSTα Protein Levels in Mild Cognitive Impairment and Alzheimer’s Disease
Author Information
Author(s): Tang Yangyang, Li Ni, Dai Linyan, Wang Xingsheng, Lai Xia
Primary Institution: Department of Geriatrics, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing, China
Hypothesis
Investigating the fluctuations of GSTα protein levels in mild cognitive impairment (MCI) and Alzheimer’s disease (AD) is essential.
Conclusion
The study found significant differences in GSTα protein levels among patients with MCI and AD, suggesting that GSTα could serve as a biomarker for early detection and intervention.
Supporting Evidence
- Plasma GSTα protein levels were significantly lower in the AD group than in the CN and MCI groups.
- Changes in GSTα protein levels were positively correlated with altered MMSE levels in MCI and AD patients.
- The AUC for predicting MCI was 0.63 and for AD was 0.74.
Takeaway
This study looked at a protein called GSTα in people with memory problems and found that changes in this protein could help doctors spot Alzheimer's disease early.
Methodology
Data were collected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, including healthy individuals, patients with MCI, and patients with AD, followed for one year.
Limitations
The study did not specifically analyze patients who converted from MCI to AD and had a relatively short follow-up period.
Participant Demographics
Participants included 54 healthy individuals, 345 patients with mild cognitive impairment, and 96 patients with Alzheimer’s disease.
Statistical Information
P-Value
p<0.001
Confidence Interval
(0.54–0.71), (0.69–0.80)
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website